PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
18.34%
Net income growth above 1.5x GNPX's 6.78%. David Dodd would see a clear bottom-line advantage if it is backed by stable operations.
-12.79%
Negative yoy D&A while GNPX is 27.35%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
35.67%
Deferred tax of 35.67% while GNPX is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
-6.19%
Both cut yoy SBC, with GNPX at -0.03%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
947.27%
Well above GNPX's 255.40% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
844.13%
A yoy AP increase while GNPX is negative at -100.00%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
-18.50%
Negative yoy usage while GNPX is 252.93%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
-6.19%
Both negative yoy, with GNPX at -1272.28%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
46.02%
Operating cash flow growth at 50-75% of GNPX's 66.89%. Martin Whitman would worry about lagging operational liquidity vs. competitor.
81.40%
CapEx growth well above GNPX's 94.63%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-34.69%
We reduce yoy other investing while GNPX is 94.05%. Joel Greenblatt sees a near-term cash advantage unless competitor’s intangible or side bets produce strong returns.
80.57%
Investing outflow well above GNPX's 94.63%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
No Data
No Data available this quarter, please select a different quarter.
-99.82%
Negative yoy issuance while GNPX is 40.51%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.